Cart
sales@molnova.com
Sodium Nitroprusside Dihydrate
CAS No. 13755-38-9
Sodium Nitroprusside Dihydrate( Sodium nitroprusside dihydrate | Sodium Nitroferricyanide(III) Dihydrate )
Catalog No. M17986 CAS No. 13755-38-9
Sodium Nitroprusside Dihydrate is a potent vasodilator working through releasing NO spontaneously in blood.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 41 | In Stock |
|
| 1G | 42 | In Stock |
|
Biological Information
-
Product NameSodium Nitroprusside Dihydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionSodium Nitroprusside Dihydrate is a potent vasodilator working through releasing NO spontaneously in blood.
-
DescriptionSodium Nitroprusside Dihydrate is a potent vasodilator working through releasing NO spontaneously in blood.(In Vitro):Nitroprusside disodium dehydrate sensitizes human gastric cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
-
In VitroNitroprusside disodium dehydrate sensitizes human gastric cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
-
In Vivo——
-
SynonymsSodium nitroprusside dihydrate | Sodium Nitroferricyanide(III) Dihydrate
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptorguanylate cyclase
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number13755-38-9
-
Formula Weight297.95
-
Molecular FormulaC5H4FeN6Na2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 46 mg/mL; 154.39 mM
-
SMILES[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Epertinib
Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
AEE-788
A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
